Lupin is prepping a $1B US deal spree; Protagonist raising $60M for trial work
→ Coming off of a $150 million deal to buy Symbiomix, Mumbai-based Lupin says it’s planning a $1 billion deal spree aimed at building a women’s health group in the US.
→ Protagonist Therapeutics $PTGX is raising $60 million through a private offering. The money will be earmarked for its clinical work on three drug candidates: PTG-100, PTG-200, and PTG-300.
→ AstraZeneca spinoff Entasis has bagged its second CARB-X award for its work on new antibiotics. The Waltham, MA-based biotech gets $3.8 million initially plus a shot at another $6.3 million.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters